Muscarinic acetylcholine receptors regulating cell cycle progression are expressed in human gingival keratinocytes.
We have previously reported the presence in human gingival keratinocytes (GKC) of choline acetyltransferase, the acetylcholine (ACh) synthesizing enzyme, acetylcholinesterase, the ACh degrading enzyme, and alpha 3, alpha 5, alpha 7, beta 2 as well as alpha 9 nicotinic ACh receptor subunits. To expand the knowledge about the role of ACh in oral biology, we investigated the presence of the muscarinic ACh receptor (mAChR) subtypes in GKC. RT-PCR demonstrated the presence of m2, m3, m4, and m5 mRNA transcripts. Synthesis of the respective proteins was verified by immunoblotting with the subtype-specific antibodies that revealed receptor bands at the expected molecular weights. The antibodies mapped mAChR subtypes in the epithelium of human attached gingiva and also visualized them on the cell membrane of cultured GKC. The whole cell radioligand binding assay revealed that GKC have specific binding sites for the muscarinic ligand [3H]quinuclidinyl benzilate, Bmax = 222.9 fmol/106 cells with a Kd of 62.95 pM. The downstream coupling of the mAChRs to regulation of cell cycle progression in GKC was studied using quantitative RT-PCR and immunoblotting assays. Incubation of GKC for 24 h with 10 micro m muscarine increased relative amounts of Ki-67, PCNA and p53 mRNAs and PCNA, cyclin D1, p21 and p53 proteins. These effects were abolished in the presence of 50 micro m atropine. The finding in GKC of mAChRs coupled to regulation of the cell cycle progression demonstrate further the structure/function of the non-neuronal cholinergic system operating in human oral epithelium. The results obtained in this study help clarify the role for keratinocyte ACh axis in the physiologic control of oral gingival homeostasis.
Arredondo
J
J
Department of Dermatology, School of Medicine, University of California, Davis, California, USA.
Hall
L L
LL
Ndoye
A
A
Chernyavsky
A I
AI
Jolkovsky
D L
DL
Grando
S A
SA
D001285:Atropine / Q000494:pharmacology; D001665:Binding Sites; D002453:Cell Cycle / Q000235:genetics; D002462:Cell Membrane / Q000378:metabolism / Q000648:ultrastructure; D019938:Cyclin D1 / Q000032:analysis; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000032:analysis; D004847:Epithelial Cells / Q000378:metabolism / Q000648:ultrastructure; D005881:Gingiva / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D015603:Keratinocytes / Q000378:metabolism* / Q000648:ultrastructure; D019394:Ki-67 Antigen / Q000032:analysis; D009116:Muscarine / Q000494:pharmacology; D018727:Muscarinic Antagonists; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D011813:Quinuclidinyl Benzilate; D012333:RNA, Messenger / Q000235:genetics; D011976:Receptors, Muscarinic / Q000145:classification* / Q000235:genetics; D013223:Statistics as Topic; D014158:Transcription, Genetic / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D019394:Ki-67 Antigen; D018727:Muscarinic Antagonists; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D011976:Receptors, Muscarinic; D016159:Tumor Suppressor Protein p53; D019938:Cyclin D1; D011813:Quinuclidinyl Benzilate; D001285:Atropine; D009116:Muscarine